West Pharmaceutical Services SG&A decreased by 7.0% to $99.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.1%, from $88.00M to $99.50M. Over 4 years (FY 2021 to FY 2025), SG&A shows relatively stable performance with a 2.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
selling_general_and_administrativeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $92.70M | $91.90M | $98.00M | $83.40M | $81.50M | $66.30M | $85.70M | $86.00M | $88.40M | $89.00M | $90.00M | $86.70M | $83.00M | $83.50M | $85.30M | $88.00M | $95.90M | $102.70M | $107.00M | $99.50M |
| QoQ Change | — | -0.9% | +6.6% | -14.9% | -2.3% | -18.7% | +29.3% | +0.4% | +2.8% | +0.7% | +1.1% | -3.7% | -4.3% | +0.6% | +2.2% | +3.2% | +9.0% | +7.1% | +4.2% | -7.0% |
| YoY Change | — | — | — | — | -12.1% | -27.9% | -12.6% | +3.1% | +8.5% | +34.2% | +5.0% | +0.8% | -6.1% | -6.2% | -5.2% | +1.5% | +15.5% | +23.0% | +25.4% | +13.1% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | — | — | — | $60.30M | $61.50M | $65.60M | $68.20M | $65.00M |
| West Vantage | — | — | — | — | — | — | — | $7.80M |
| Contract-Manufactured Products | $6.20M | $6.70M | $7.10M | $7.60M | $7.00M | $7.50M | $7.80M | — |
| Total | $83.00M | $83.50M | $85.30M | $88.00M | $95.90M | $102.70M | $107.00M | $99.50M |
Contract-Manufactured Products was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
SG&A at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's sg&a?
- West Pharmaceutical Services (WST) reported sg&a of $99.50M in Q1 2026.
- How has West Pharmaceutical Services's sg&a changed year-over-year?
- West Pharmaceutical Services's sg&a increased by 13.1% year-over-year, from $88.00M to $99.50M.
- What is the long-term trend for West Pharmaceutical Services's sg&a?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's sg&a has grown at a 2.1% compound annual growth rate (CAGR), from $362.80M to $393.60M.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.